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Abstract
Sodium channels are one of the most intensively studied drug targets. Sodium channel inhibitors (e.g., local anesthetics,
anticonvulsants, antiarrhythmics and analgesics) exert their effect by stabilizing an inactivated conformation of the
channels. Besides the fast-inactivated conformation, sodium channels have several distinct slow-inactivated conformational
states. Stabilization of a slow-inactivated state has been proposed to be advantageous for certain therapeutic applications.
Special voltage protocols are used to evoke slow inactivation of sodium channels. It is assumed that efficacy of a drug in
these protocols indicates slow-inactivated state preference. We tested this assumption in simulations using four
prototypical drug inhibitory mechanisms (fast or slow-inactivated state preference, with either fast or slow binding kinetics)
and a kinetic model for sodium channels. Unexpectedly, we found that efficacy in these protocols (e.g., a shift of the
‘‘steady-state slow inactivation curve’’), was not a reliable indicator of slow-inactivated state preference. Slowly associating
fast-inactivated state-preferring drugs were indistinguishable from slow-inactivated state-preferring drugs. On the other
hand, fast- and slow-inactivated state-preferring drugs tended to preferentially affect onset and recovery, respectively. The
robustness of these observations was verified: i) by performing a Monte Carlo study on the effects of randomly modifying
model parameters, ii) by testing the same drugs in a fundamentally different model and iii) by an analysis of the effect of
systematically changing drug-specific parameters. In patch clamp electrophysiology experiments we tested five sodium
channel inhibitor drugs on native sodium channels of cultured hippocampal neurons. For lidocaine, phenytoin and
carbamazepine our data indicate a preference for the fast-inactivated state, while the results for fluoxetine and desipramine
are inconclusive. We suggest that conclusions based on voltage protocols that are used to detect slow-inactivated state
preference are unreliable and should be re-evaluated.
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Introduction
Sodium channels are the key proteins in action potential firing
for most excitable cells. They exhibit a complex, membrane
potential-dependent gating behavior [1]. Even minor disturbances
in the gating behavior can lead to hyperexcitability, which can be
one of the causes of various disorders such as epilepsy, migraine,
neuropathic and inflammatory pain, muscle spasms, and chronic
neurodegenerative diseases. For several decades, sodium channel
inhibitors (SCIs) have been successfully used to lower excitability
as, for example, local anesthetics, anticonvulsants, antiarrhyth-
mics, analgesics, antispastics and neuroprotective agents. Interest-
ingly, the majority of antidepressants were also found to be potent
SCIs. In a recent study [2] the highest incidence of SCI activity
was found amongst this therapeutic class. We intend to test if the
mechanism of action on sodium channels is similar to that of
classic SCIs.
Thus far only a single drug binding site is established
unequivocally on sodium channels, the ‘‘local anesthetic receptor’’,
located within the inner vestibule, its key residue being the
phenylalanine located right below the selectivity filter, on domain
4 segment 6 [3]. However, the contribution of individual residues
within the inner vestibule changes from drug to drug [4–6]. For
certain drugs an alternative binding site have been proposed,
which is supposed to be located within the outer pore [7,8], but the
exact position of the binding site(s) for specific SCIs (other than
local anesthetics) is currently unsettled. For our case the exact
location of the binding site is not relevant, we only need to suppose
that the major mechanism of inhibition is preferential affinity to-,
and stabilization of a specific inactivated state.
The major mechanism of SCIs is stabilization of an inactivated
channel conformational state as a result of a preferential affinity
for that state. The question of which inactivated state is preferred
is under debate for many SCI drugs (e.g. [9–12], or [13–17]).
Sodium channels are capable of fast inactivation (complete within
a few milliseconds), and different forms of slow inactivation (time
constants ranging from ,100 ms to several minutes) [18]. Slow-
inactivated state preference has been proposed as a therapeutic
advantage [19–21]. Mutations of sodium channel genes which
affect slow inactivation are associated with several diseases [22].
Slow inactivation determines sodium channel availability, and
thereby contributes to overall membrane excitability, determining
the propensity to generate repetitive firing, and the extent of action
potential backpropagation. Slow inactivated state preference has
been proposed as a potential therapeutic advantage in specific
types of epilepsy, neuropathic pain and certain arrhythmias
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inhibition has been proposed to modulate neuronal plasticity
[22]. In recent years a number of novel slow-inactivated state-
preferring drug candidates have been described, including the
recently approved antiepileptic drug lacosamide (Vimpat) [19,23].
This drug has been found to be effective in a model of treatment-
resistant seizures, and of diabetic neuropathic pain, in which tests
conventional anticonvulsants were found ineffective [19].
Special voltage protocols are used to evoke and study the slow-
inactivated state. Availability of channels is studied after a
prolonged depolarization (to induce slow inactivation), followed
by a hyperpolarizing gap (to allow recovery from fast, but not slow
inactivation). Because availability in such protocols is solely
determined by the extent of slow inactivation, a drug that
decreases availability is considered to be slow-inactivated state-
preferring. However, gating rates (the rate of inactivation and rate
of recovery from inactivation) are altered by drug binding. A fast-
inactivated state-preferring drug stabilizes this state by delaying
recovery. A delayed recovery does not necessarily indicate actual
modification of the gating rate. For example if the bound drug
prevents recovery from inactivation, then recovery will appear to
be slowed because the drug needs first to dissociate [24,25]. In our
current study, however, we chose to use a model according to the
modulated receptor hypothesis [26,27], i.e., the change in affinity
equals the actual modification of the gating rates. For this reason
in our model increased affinity is synonymous with state
stabilization. Altered gating rates have been experimentally
demonstrated using gating charge measurements [28,29]. Because
of the altered gating, the rate of recovery from fast inactivation in
the presence of the drug can easily overlap with the rate of
recovery from slow-inactivated state. The rate of state-dependent
association and dissociation of the drug should also be taken into
account. As a result, interpretation of data obtained with these
protocols is not straightforward (e.g. [9,30]).
With the help of simulations, we intended to understand the
interactions between binding and gating rates and wanted to test
the major prototypical inhibitor mechanisms in commonly used
protocols. We wanted to explore what could be deduced from
these data, and wanted to find the right protocols that could help
to determine the inhibition mechanisms.
Our data suggest that conclusions based on conventional
protocols are not reliable. For example, the fact that one drug
preferentially shifts the ‘‘steady-state slow inactivation curve’’ as
compared to another drug does not necessarily mean that the
drug prefers the slow-inactivated state. Figure 1 illustrates two
(simulated) drugs investigated in ‘‘steady-state inactivation’’ pro-
tocols (protocols are discussed below). Both drugs shifted the ‘‘fast
inactivation curve’’ (Figure 2, ‘‘FInact_V’’) to the same degree, but
Drug 1 caused a larger shift in the ‘‘slow inactivation curve’’
(Figure 2, ‘‘SInact_V’’). In this special case, however, Drug 1 was
defined to have a higher affinity to fast inactivated state, while
Drug 2 had a higher affinity to slow inactivated state. We
observed, on the other hand, that fast- and slow-inactivated state-
preferring drugs tended to preferentially affect the onset of
inactivation and recovery, respectively. Therefore we combined
the information from these two protocols by plotting effectiveness
in one protocol as a function of effectiveness in the other. We
observed that data points for fast- and slow-inactivated state-
preferring drugs were confined to definite areas of the effectiveness
(inactivation) – effectiveness (recovery) plane. The two areas
were found to overlap; therefore, explicit determination of the
mechanism was not possible in all cases.
Using patch-clamp experiments, we tested three classic SCIs
(lidocaine, phenytoin and carbamazepine) and two antidepressants
(fluoxetine and desipramine). Properties of inhibition by classic
SCIs were consistent with fast-inactivated state preference with fast
binding kinetics. Inhibition by antidepressants was distinctly
different. Whether the difference was caused by slow binding
kinetics or slow-inactivated state preference could not be
determined.
Results
Models
For simulations two different kinds of models were used: a
phenomenological Hodgkin-Huxley type model and a state model
similar to the one published by Kuo and Bean [31]. In both
models, however, we introduced slow-inactivated states and drug-
bound states with altered gating transition rates. For a detailed
description of the models see Methods and Text S1. The Hodgkin-
Huxley type model, which will be referred to as the ‘‘tetracube’’
model because of its topology (see Methods), was used for most
simulations. The Kuo-Bean type model, referred to as the ‘‘multi-
step-activation’’ (MSA) model, was only used for testing the
robustness of our observations. In the models, both the degree of
alteration of the transition rates and the state preference (the
difference between affinities for different states) were given by a
single factor CF (for fast-inactivated state-preferring drugs) or CS
(for slow-inactivated state-preferring drugs). The kinetics of
association and dissociation to the resting state are defined by
the rate constants ka and kd, respectively. Association and
dissociation rate constants to other states were calculated as
described in Methods.
Test protocols
To compare simulated data with experimental results, we used
similar voltage protocols in both the simulations and experiments
(Figure 2). Throughout this study we used four protocols:
‘‘FInact_V’’ is a standard ‘‘steady-state fast inactivation’’
protocol in which availability is assessed as a function of pre-
pulse membrane potential. The pre-pulse duration was 0.1 s when
Author Summary
Sodium channels are the key proteins for action potential
firing in most excitable cells. Inhibitor drugs prevent
excitation (local anesthetics), regulate excitability (antiar-
rhythmics), or prevent overexcitation (antiepileptic, anti-
spastic and neuroprotective drugs) by binding to the
channel and keeping it in one of the inactivated channel
conformations. Sodium channels have one fast- and
several slow-inactivated conformations (states). The spe-
cific stabilization of slow-inactivated states have been
proposed to be advantageous in certain therapeutic
applications. The question of whether individual drugs
stabilize the fast or the slow-inactivated state is studied
using specific voltage protocols. We tested the reliability of
conclusions based on these protocols in simulation
experiments using a model of sodium channels, and we
found that fast- and slow-inactivated state-stabilizing
drugs could not be differentiated. We suggested a method
by which the state preference of at least a subset of
individual drugs could be determined and tried the
method in electrophysiology experiments with five indi-
vidual drugs. Three of the drugs (lidocaine, phenytoin and
carbamazepine) were classified as fast-inactivated state-
stabilizers, while the state preference of fluoxetine and
desipramine was found to be undeterminable by this
method.
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electrophysiology experiments, because drugs with differing
mechanisms of action and association kinetics had to be
compared, a 2 s pre-pulse duration was used. Note, that although
we use the widespread term ‘‘steady-state fast inactivation’’
protocol, the term is incorrect for two reasons. First, it is not
necessarily ‘‘steady-state’’ in the sense that the pre-pulse duration
may not be long enough for reaching equilibrium of either drug
binding or channel gating (2 s is enough for the development of
some degree of slow inactivation). Second, ‘‘availability’’ would be
a better term than ‘‘inactivation’’, because the protocol does not
necessarily reflect only inactivation in the presence of a drug, since
we cannot separate blocked open and inactivated channels;
however, ‘‘fast availability’’ and ‘‘slow availability’’ protocols are
improper terms.
‘‘SInact_V’’ is a ‘‘steady-state slow inactivation’’ protocol in
which occupancy of the slow-inactivated state is intended to be
measured as a function of the membrane potential. It differs from
the previous protocol in two respects: pre-pulse duration is longer
(10 s), allowing more complete development of slow inactivation;
and this protocol contains a 10 ms hyperpolarizing (2150 mV)
gap between the pre-pulse and the test pulse. The hyperpolarizing
gap serves to separate occupancy of the slow-inactivated state from
that of fast-inactivated states: .95% of channels recover from the
fast-inactivated state within this period. Despite the name,
however, neither ‘‘FInact_V’’ nor ‘‘SInact_V’’ is able to measure
drug effects on a pure population of fast or slow-inactivated
channels. Fast inactivation practically reaches equilibrium at most
membrane potentials within ,10 ms. With longer durations of
pre-pulses in the ‘‘FInact_V’’ protocols the ratio of slow-
inactivated channels increases from ,5% (0.1 s pre-pulse) to
,40% (2 s pre-pulse). This is accompanied by a minor shift of
the curve (DV1/2,4 mV). Drug effects can further change this
distribution depending on binding kinetics and state preference. In
‘‘SInact_V’’ protocols most unavailable channels are in a slow-
inactivated state in the absence of drugs. However, the presence of
a drug may alter the distribution of channel states. The
unavailable fraction does not consist of slow-inactivated channels
only but also is ‘‘contaminated’’ with drug-bound fast-inactivated
channels. The conventional name ‘‘steady-state’’ therefore is
absolutely untrue for this protocol, as the extent and V1/2 of slow
inactivation is strongly dependent on pre-pulse duration. We
Figure 1. Effectiveness of two simulated drugs in ‘‘steady-state fast inactivation’’ and ‘‘steady-state slow inactivation’’ protocols. A
typical example showing that state preference of drugs cannot reliably be deduced from these protocols (see Figure 2). Drug 1 has preferential
affinity to fast inactivated state, while Drug 2 prefers slow inactivated state. A, ‘‘steady-state fast inactivation’’ protocol. B, ‘‘steady-state slow
inactivation’’ protocol.
doi:10.1371/journal.pcbi.1000818.g001
Figure 2. Protocols used in experiments and simulations. For explanation see text.
doi:10.1371/journal.pcbi.1000818.g002
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above.
‘‘SInact_t’’ (‘‘Slow inactivation onset as a function of time’’)
monitors the effect of prolonged depolarizations on sodium
channel availability. In the absence of drugs, the onset of slow
inactivation is monitored as a function of time (duration of
depolarizing pulses). In the presence of a drug, it is not clear
whether it reflects pure slow inactivation or a mixture of fast and
slow inactivation (see below for a detailed explanation).
‘‘Rec_t’’ (‘‘Recovery from inactivation as a function of time’’)
monitors recovery after a 5 s depolarization to 220 mV as a
function of hyperpolarizing gap duration (the gap is between the
5 s pre-pulse and the test pulse). In the absence of drugs, a 5 s
depolarization causes both fast and slow inactivation (approxi-
mately 45–55%, respectively), and the protocol monitors recovery
from both states. The time constants for recovery were 2.21 and
58.25 ms [32]. In the presence of drugs, measured recovery
reflects the combination of dissociation and recovery from both
inactivated states.
Concentration-response curves were simulated using single
depolarizations to 0 mV from holding potentials of 2150, 290
and 260 mV.
Simulation experiments: Four prototypical mechanisms
Defining the prototypical mechanisms. In order to
address the problem of fast- vs. slow-inactivated state preference
and the interaction between the dynamics of binding and gating,
we simulated four prototypical mechanisms: either the fast- or the
slow-inactivated state was preferred by the drug (‘‘FI’’ and ‘‘SI’’,
respectively), and the drug had either fast or slow binding kinetics
(‘‘fb’’ and ‘‘sb’’, respectively). Fast-inactivated state preference was
introduced by setting CF=10 (with CS=1). Slow-inactivated state-
preferring drugs were defined by CS=10(CF=1). Association and
dissociation rate constants for drugs with fast binding kinetics were
set to the values: ka=0.5 s
21mM
21 and kd=100 s
21, while
slow binding kinetics were defined as ka=0.005 s
21mM
21 and
kd=1s
21. The term ‘‘fast’’ is relative, of course. All SCIs associate
relatively slowly compared to hydrophilic drugs that bind to a
readily accessible extracellular site. We chose these values so that
they would be close to the rate constants that had been determined
in previous studies for classic sodium channel inhibitors (e.g. [12]).
Combinations of these properties give the four prototypical
‘‘drugs.’’ Current hypotheses for the mechanism of antide-
pressant action are represented by either the drug ‘‘FI_sb’’ (fast-
inactivated state is stabilized, with slow binding kinetics) or the
‘‘SI_fb’’ drug (slow-inactivated state is stabilized, and binding
kinetics are not rate limiting). A third hypothesis for the
mechanism of antidepressants is also evaluated because it is also
possible that both slow-inactivated state preference and slow
binding kinetics determine the onset rate of inhibition (‘‘SI_sb’’).
Inhibition by anticonvulsants has a rapid onset, but the identity
of the preferred state is debated. Alternative anticonvulsant
hypotheses, therefore, are represented by either ‘‘SI_fb’’ or
‘‘FI_fb.’’
Slow association and slow inactivation preferences could
not be discriminated by conventional voltage protocols.
Simulations with the tetracube model, obtained under control
conditions and in the continuous presence of 30 mM of any of the
four prototypical ‘‘drugs,’’ are shown in Figure 3 A–D.
No difference in the concentration-response curves between the
drugs with fast and slow association rates was found at very
negative holding potentials (2150 mV), at which there is no
significant inactivation (Figure 3A). At less hyperpolarized
membrane potentials (290 and 260 mV), the relative potency
of drugs was model parameter dependent, determined by the
fraction of inactivated channels: When the V1/2 value for slow
inactivation was more negative, ‘‘SI’’ drugs were more potent
(data not shown). When V1/2 for fast inactivation was more
negative (which was the case when we used the particular
parameters obtained by optimization – Table S3), ‘‘FI’’ drugs
seemed to be more potent (Figure 3A). Binding kinetics had minor
influence on concentration response curves.
If a drug has no effect on the ‘‘steady-state fast inactivation
curve’’, but it shifts the ‘‘steady-state slow inactivation’’ curve
substantially, one might think that the reason for this must be slow-
inactivated state preference. To test this argument, we simulated
both ‘‘steady-state fast inactivation’’ and ‘‘steady-state slow
inactivation’’ curves. For the ‘‘FInact_V’’ curve, a 100 ms long
conditioning pulse (ranging from 2120 mV to 230 mV) preceded
the test pulse (Figure 3B left panel). For the slow inactivation
curve, the duration of the conditioning pulse was extended to 10 s,
and a 10 ms hyperpolarization to 2150 mV was inserted before
the test pulse to allow recovery from the fast-inactivated state
(Figure 3B right panel). The only drug that shifted the ‘‘steady-
state fast inactivation’’ curve appreciably was ‘‘FI_fb.’’ ‘‘FI_sb’’
failed to affect this curve because its association was not fast
enough to act significantly within the time of the pre-pulse
(100 ms). The slow inactivation curve was shifted by all four drugs.
The protocol, thus, failed to distinguish slow-inactivated state-
preferring and slowly associating drugs.
In the ‘‘SInact_t’’ protocol, the four drugs shifted the curve in
clearly dissimilar patterns (Figure 3C). Unexpectedly, fast-
inactivated state-stabilizing drugs caused a larger shift of the
‘‘slow inactivation curve’’ than slow-inactivated state-preferring
drugs. The reason for this counter-intuitive behavior is that, once
the recovery from the fast-inactivated state is slowed down, the
curve no longer reflects the ratio of slow-inactivated channels,
but instead reflects a mixture of slow and fast-inactivated
channels. The lack of effect on the process of slow inactivation
can be seen in the biphasic pattern of the curve in the presence
of drug ‘‘FI_fb.’’ This pattern is remarkably similar to the curve
obtained experimentally with 300 mM lidocaine or 300 mM
carbamazepine using the protocol with the 5 ms hyperpolarizing
gap (see below).
In the ‘‘Rec_t’’ protocol, ‘‘FI_fb’’ behaved as expected, affecting
only the part of the curve that is responsible for recovery from the
fast-inactivated state. However, drug ‘‘FI_sb’’ was as effective as
slow-inactivated state-preferring drugs. In experiments using this
protocol, the recovery from inhibition is slowed down for two
reasons: i) the slow dissociation rate of the drug; and ii) drug-
bound channels display a slowed gating. In the case of ‘‘FI_sb,’’
the former seems to be the rate-limiting step and, if dissociation is
slow enough, the curve is shifted, whichever state is preferred
(Figure 3D).
Although recovery from fast inactivation is almost complete
(95%) within the 10 ms gap, some studies used longer gaps
(100 ms to 1 s) in ‘‘steady-state slow inactivation’’ (‘‘SInact_V’’) or
onset of slow inactivation (‘‘SInact_t’’) protocols in order to make
sure that even drug-bound fast-inactivated channels had time to
recover. However, this time is still insufficient for drugs with slow
dissociation kinetics. To test how the relative potency of the four
drugs depends on gap duration, we made simulations with
different gap durations ranging from 1 ms to 10 s. The curves
shown in Figure 3C were generated using different gap durations.
The potency of the drugs was quantified by calculating the sum of
differences between control and drug curves, and the values were
plotted against gap duration in Figure 3E. While the effect of drug
‘‘FI_fb’’ disappeared at gap durations above 100 ms, ‘‘FI_sb’’
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PLoS Computational Biology | www.ploscompbiol.org 4 June 2010 | Volume 6 | Issue 6 | e1000818Figure 3. Results of simulations with the tetracube model using the four prototypical mechanisms. The mechanisms were: ‘‘FI_fb’’ (fast-
inactivated state is stabilized, with fast binding kinetics), ‘‘FI_sb’’ (fast-inactivated state is stabilized, with slow binding kinetics), ‘‘SI_fb’’ (slow-
inactivated state is stabilized, with fast binding kinetics) and ‘‘SI_sb’’ (slow-inactivated state is stabilized, with slow binding kinetics). A, Concentration
response curves. B, Effect of simulated ‘‘drugs’’ on ‘‘steady-state fast inactivation’’ (left panel) and ‘‘steady-state slow inactivation’’ (right panel)
protocols. C, Effect of simulated ‘‘drugs’’ on the slow inactivation onset curve. D, Effect of simulated ‘‘drugs’’ on the recovery curve. E, Dependence of
the effect of simulated ‘‘drugs’’ on the duration of the hyperpolarizing gap. The effect was quantified by calculating the areas between curves from
the semilogarithmic plots. Box indicates data calculated from curves seen in Figure 3C.
doi:10.1371/journal.pcbi.1000818.g003
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durations.
In summary, conventional voltage protocols failed to reliably
distinguish between drugs ‘‘FI_sb’’ and ‘‘SI_fb.’’In particular,
results of the ‘‘SInact_t’’ protocol are not only unreliable, but are
clearly misleading as ‘‘FI_sb’’ caused a much larger shift than
‘‘SI_fb.’’
Test of robustness #1: Simulations with the MSA
model. We made three major observations in the simulations
described above: 1) A shift of the ‘‘SInact_V’’ curve does not
necessarily reflect a slow-inactivated state preference; 2) Fast-
inactivated state-stabilizing drugs caused a larger shift of the
‘‘SInact_t’’ curve than slow-inactivated state-preferring drugs; and
3) Slow-inactivated state-preferring drugs are not necessarily more
effective than fast-inactivated state-preferring ones in delaying
recovery in the ‘‘Rec_t’’ protocol.
In order to judge the reliability of these observations, we first
repeated the experiments using the MSA model, an allosteric
model where inactivation processes draw their voltage-dependen-
cies from the voltage-dependence of the activation process. Results
of the simulations are shown in Figure S2. Although simulation
results with the MSA model gave somewhat different results (see
Text S1), the three major observations were evidently confirmed.
Test of robustness #2: Simulations with the tetracube
model with random parameters. We also tested the
consistency of our observations by varying parameters of the
tetracube model. We wanted to test at which part of the parameter
space they were true and under what conditions they failed. To
this end, we performed Monte Carlo simulations. All 18
parameters were randomized between the constraints shown in
Table S3. With each set of randomized parameters the following
protocols were simulated: 1) ‘‘SInact_V’’ using drug ‘‘FI_sb;’’ 2)
‘‘SInact_t’’ using all four drugs; and 3) ‘‘Rec_t’’ using all four
drugs. One hundred individual sets of random parameters were
generated. Most of these produced channels with abnormal
voltage-dependences or kinetics of gating. (We only constrained
parameters for the rate constants. The kinetics and equilibrium of
any of the three gates, however, are determined by six parameters.
Even if each of the six parameters is within the normal range, their
combinations can result in abnormal gating.) Figure 4 illustrates
the results of the 100 simulations.
The first question was how the observation that ‘‘FI_sb’’ can
cause a shift of the ‘‘SInact_V’’ (‘‘steady-state slow inactivation’’)
curve depends on model parameters. Out of the 100 simulations,
23 random sets of parameters did not result in substantial slow
inactivation, so the shift of V1/2 could not be determined. In 50
out of the remaining 77 simulations, the shift was larger than
25 mV (Figure 4A). We plotted the values for the shift of
inactivation curves against the difference between the V1/2 of the
equilibrium curves for slow and fast inactivation (calculated from
the randomly generated parameters of rate constants). Although a
significant shift by ‘‘FI_sb’’ more frequently occurred when the
V1/2 for fast inactivation was more negative (i.e., in the right-hand
side of the plot), in several cases it can be seen even at the other
side. We can conclude that, in roughly two-thirds of the cases, fast-
inactivated state-preferring drugs did shift the ‘‘SInact_V’’ curve.
This suggests that a shift of the ‘‘steady-state slow inactivation’’
curve is certainly not a good indicator of slow-inactivated state
preference.
To verify the second and third observations, the effect of all four
prototypical drugs was tested in protocols ‘‘SInact_t’’ and
‘‘Rec_t.’’ The extent of the shift caused by individual drugs was
quantified by calculating the sum of differences (SOD) between the
curves in the control conditions and during drug application.
Because the sampling points were evenly distributed on the
logarithmic scale, the SOD was proportional to the area between
the curves displayed on a semi logarithmic plot. For the sake of
comparability, we calculated the normalized sum of differences
(nSOD) by dividing SOD values by the sum of the control values
(i.e., the full ‘‘area’’ under the control curve). The value of nSOD
varied between 0 and 1; nSOD equaled 0 if the drug had no effect
Figure 4. Results of 100 simulations with random parameters
of the tetracube model. Measures of the potency of the four
prototypical ‘‘drugs’’ are plotted against the difference between V1/2
values for fast and slow inactivation. A, Leftward shift of the V1/2 of
‘‘FInact_V’’ and ‘‘SInact_V’’ curves, caused by ‘‘FI_sb.’’ B, Effect of all four
‘‘drugs’’ on the ‘‘SInact_t’’ curve. The effect was quantified by
calculating the sum of differences between control and drug curves
(see Figure 3C). C, Effect of all four ‘‘drugs’’ on the ‘‘Rec_t’’ curve. Sum of
differences between the curves in control conditions, and during drug
application. (see Figure 3D).
doi:10.1371/journal.pcbi.1000818.g004
Na
+ Channel Inhibitor Mechanisms
PLoS Computational Biology | www.ploscompbiol.org 6 June 2010 | Volume 6 | Issue 6 | e1000818on slow inactivation or recovery, and equaled 1 if the current was
completely abolished by the drug. Values of nSOD for the four
prototypical drugs are shown in Figures 4B and C. For shifting the
‘‘SInact_t’’ curve, ‘‘FI_fb’’ was the most efficient drug for 90 out of
100 sets of parameters, while ‘‘FI_sb’’ and ‘‘SI_fb’’ were most
efficient in 6 and 4 sets of parameters, respectively. The typical
order of potency (for 55 out of 100 sets of parameters) was
‘‘FI_fb’’.‘‘FI_sb’’.‘‘SI_fb’’.‘‘SI_sb.’’ For shifting the ‘‘Rec_t’’
curve, ‘‘FI_sb’’ was most often (for 70 out of 100 sets) the most
effective. The ‘‘SI_sb’’ and ‘‘SI_fb’’ were found to be most efficient
in 20 and 8 sets, respectively. Note that, for both tests, one of the
fast-inactivated state-preferring drugs typically performed better
than either of the slow-inactivated preferring ones.
Summarizing the results of the Monte Carlo simulations, all
three observations were verified for all models. We have
demonstrated that ‘‘FI_sb’’ type drugs can behave like ‘‘SI’’ type
drugs in ‘‘FInact_V’’ and ‘‘SInact_V’’ protocols. Therefore these
protocols cannot be used for distinguishing ‘‘FI’’ and ‘‘SI’’ drugs.
Nevertheless, we also observed definite tendencies, e.g., ‘‘FI’’ drugs
tend to be more effective in ‘‘SInact_t’’ protocols than in ‘‘Rec_t’’
protocols, or ‘‘FI_sb’’ drugs tend to be the most effective in
‘‘Rec_t’’ protocols (Figure 3–4). We explored how much the
combined information from the two protocols could tell us about
SCI state preferences.
Parameter-dependence of effectiveness in ‘‘SInact_t’’ and
‘‘Rec_t’’ protocols
We plotted the nSOD values of the ‘‘Rec_t’’ protocol as a
function of the nSOD values of the ‘‘SInact_t’’ protocol. (Figure 5).
We investigated the effect of changing the following parameters: i)
binding kinetics of drugs, ii) state preference factors (CF and CS),
iii) drug concentration, iv) sodium channel model parameters, and
v) hyperpolarizing gap duration in the ‘‘SInact_t’’ protocol.
Binding kinetics: We simulated 10 different pairs of rate constants
spanning five orders of magnitude from 5*10
24 to 15 mM
21s
21
(ka) and from 0.1 to 3000 s
21 (kd). The ratio of ka and kd was kept
constant ka/kd=5*10
23, ensuring that the affinity of the drug
toward the resting channel remained constant.
State preference factors: CF and CS were given the following values:
2, 5, 10, 20 or 50. Using the five CF and the five CS values, each
with the ten pairs of ka and kd values, we simulated altogether 100
‘‘drugs’’ in both ‘‘SInact_t’’ and ‘‘Rec_t’’ protocols. To correct for
different potencies, the concentration of each drug was scaled: we
used the concentration that caused 50% inhibition of single
depolarizations at 290 mV holding potential (Table S5).
Figure 5A shows the distribution of ‘‘Rec_t’’ nSOD vs.‘‘SInact_t’’
nSOD values. As the binding kinetics were accelerated, data points
for specific CF/CS values proceeded clockwise along a closed loop.
The explanation is that binding kinetics have a range of optimal
effectiveness; kinetics that are too slow do not allow for sufficient
association during depolarizations, while kinetics that are too fast
cause drug molecules to dissociate more during hyperpolariza-
tions. Around the optimum conditions, effectiveness in the
‘‘SInact_t’’ protocol increases with an acceleration in the kinetics
in parallel with a decrease of effectiveness in the ‘‘Rec_t’’ protocol.
When CF and CS values were changed without concentration
correction, the absolute value of the change was proportional to
the value of CF and CS, but the characteristic clockwise loop
pattern was unchanged (Figure 5B).
Drug concentration: The effect of changing concentrations while
keeping CF or CS constant (CF=10 or CS=10) is shown in
Figure 5C. The concentration was decreased and increased
tenfold. The effect increased with increasing concentration, while
acceleration of the binding kinetics caused the points to move
along the clockwise loop as described above.
When all simulation results were plotted on the nSOD(Rec_t) –
nSOD(SInact_t) plane, we observed that fast- and slow-inactivated
state-stabilizing drugs were confined to limited but overlapping
areas of the plane (Figure 5D). Because of the clockwise
progression of the points upon acceleration of the binding kinetics,
the overlapping area contains mostly ‘‘FI_sb’’ and ‘‘SI_fb’’ type
drugs.
Sodium channel model parameters: To test the influence of channel
parameters, we plotted the results from Monte Carlo simulations
of the four prototypical drugs on the nSOD(Rec_t) – nSOD(SI-
nact_t) plane, and compared those with the areas based on
Figure 5D. ‘‘FI’’ drugs were almost exclusively located within the
‘‘fast area,’’ while ‘‘SI’’ drugs were located within the ‘‘slow area,’’
practically irrespective of model parameters. The overlapping area
was populated mostly by ‘‘FI_sb’’ and SI_fb’’ drugs, confirming
the reliability of ‘‘fast’’ and ‘‘slow’’ areas (Figure 5E).
Hyperpolarizing gap duration of the ‘‘SInact_t’’ protocol: In simulations
and experiments, we used a 10 ms gap duration, which is enough
for a .90% recovery from the fast-inactivated state under control
conditions. In the presence of a fast-inactivated state-stabilizing
drug, recovery is slowed down. For this reason, in experiments
where slow-inactivated state-stabilizing drugs are to be identified,
gap duration is often chosen to be of a longer duration (up to 1 s)
to ensure that the recovery from fast inactivation is complete. Our
simulations indicated that ‘‘FI_sb’’ and ‘‘SI’’ type drugs neverthe-
less overlap in behavior no matter what hyperpolarizing gap
duration is chosen (see Figure 3E). We tested the effect of setting
the gap duration to 1 s (Figure 5F). ‘‘FI’’ and ‘‘SI’’ type drugs were
no better separated with a 1 s than with the 10 ms gap duration.
In summary, localization on the nSOD(Rec_t) – nSOD(SI-
nact_t) plane can reveal the state preference of a drug if it falls on
one of the non-overlapping areas. However, many ‘‘SI_fb’’ and
‘‘FI_sb’’ type drugs are expected to fall in the overlapping section
and, therefore, their state preference cannot be determined.
Electrophysiology experiments with SCIs
The following SCI drugs were used: the local anesthetic and
antiarrhythmic lidocaine (300 mM), the anticonvulsants phenytoin
(300 mM) and carbamazepine (300 mM), and the antidepressants
fluoxetine (30 mM) and desipramine (30 mM). The concentrations
were chosen to be similarly effective in causing a hyperpolarizing
shift (210 to 218 mV) of the ‘‘steady-state inactivation’’ curve
(‘‘FInact_V’’ – 2 s pre-pulse) (Figure 6A).
In the ‘‘SInact_t’’ protocol (Figure 6B), carbamazepine and
phenytoin caused only a small acceleration in the process of
inactivation. Fluoxetine and desipramine caused an obvious shift,
similar to the one caused by the prototypical drugs ‘‘FI_sb,’’
‘‘SI_fb’’ and ‘‘SI_sb.’’ Lidocaine strongly shifted the curve
(especially in the early phase), which is typical of ‘‘FI_fb’’ type
drugs. The reason for the small effect of carbamazepine was its fast
dissociation kinetics. When the hyperpolarizing gap duration was
changed from 10 ms at 2150 mV to 5 ms at 2120 mV (similar to
the protocol used by Kuo et al. [12]), carbamazepine became as
effective as lidocaine (Figure 6B inset).
In the ‘‘Rec_t’’ protocol (Figure 6C), fluoxetine and desipra-
mine shifted the curve of recovery, similar to the prototypical
drugs ‘‘FI_sb,’’ ‘‘SI_sb’’ and ‘‘SI_fb.’’ Carbamazepine, phenytoin
and lidocaine only altered the early phase of the recovery curve,
similar to the drug ‘‘FI_fb.’’
We created the nSOD(Rec_t) – nSOD(SInact_t) plots for all five
drugs (Figure 6D). The data points for fluoxetine and desipramine
were in the overlapping area. The data points for carbamazepine,
Na
+ Channel Inhibitor Mechanisms
PLoS Computational Biology | www.ploscompbiol.org 7 June 2010 | Volume 6 | Issue 6 | e1000818phenytoin and lidocaine fell into the non-overlapping area of fast
inactivation stabilizing drugs.
Discussion
Slow-inactivated state preference has been proposed to be a
therapeutic advantage [19–21], and therefore different drugs have
been tested for this property. The question of fast- or slow-
inactivated state preference is a complex problem because of the
interdependence of binding and gating equilibria. Multiple
interconnected equilibria can be relatively easily handled by
modeling; therefore, we used this approach to test hypotheses
regarding state preference. Our current simulation data suggest
that conclusions based on conventional protocols [19–21,33–35]
are not reliable.
A shift of the ‘‘steady-state slow inactivation curve’’ (‘‘SInact_V’’
protocol), a shift of the ‘‘slow inactivation onset’’ curve (‘‘SInact_t’’
protocol) and a shift of the recovery curve (‘‘Rec_t’’ protocol)
Figure 5. Different effectiveness of ‘‘FI’’ and ‘‘SI’’ drugs in two voltage protocols. Plots of effectiveness (quantified as nSOD, as described in
text) in the ‘‘Rec_t’’ protocol plotted against effectiveness (nSOD) in the ‘‘SInact_t’’ protocol for various simulated drugs. Drugs with the same state
preference factor (CF or CS) and concentration are connected. A, Distribution of 100 simulated drugs with different state preference factors and
binding kinetics, applied in their IC50 (290 mV) concentration. B, The effect of different state preference factors. Simulated drugs were applied in
14 mM concentrations in the case of fast inactivation preferring, and in 81.75 mM concentrations in the case of slow inactivation preferring drugs. C,
The effect of different concentrations. The state preference factor was set to 10 in case of both fast and slow inactivation preferring drugs. D, All
simulated drugs plotted on one figure. The areas of fast- and slow-inactivated preferring drugs were determined using all data points simulated. E,
Prototypical drugs (‘‘FI_fb,’’ ‘‘FI_sb,’’ ‘‘SI_fb,’’ and ‘‘SI_sb’’) simulated using the 100 channel models from the Monte Carlo simulation. The two areas
were defined based on the points shown in panel D. F, Effect of increasing the hyperpolarizing gap in the ‘‘SInact_t’’ protocol from 10 ms to 1 s. The
100 simulated drugs from panel A were applied in their IC50 (290 mV) concentration.
doi:10.1371/journal.pcbi.1000818.g005
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stabilization. This conclusion was confirmed both by testing
whether our observations were true for the entire parameter space
and by applying a different type of model. We found that, with all
combinations of parameters (within the reasonable range), our
observations held true. Furthermore, both the phenomenological
tetracube model and the MSA state model gave qualitatively
similar results.
Nevertheless, the four prototypical mechanisms behaved
appreciably differently. For this reason, we investigated the extent
to which the two major mechanisms (‘‘FI’’ and ‘‘SI’’) could be
distinguished using the combined information from different
voltage protocols. Based on the nSOD(Rec_t) – nSOD(SInact_t)
plots, we concluded that ‘‘FI’’ type drugs can be recognized,
provided that their binding kinetics are fast enough. However,
‘‘FI’’ drugs with slower binding kinetics will overlap with ‘‘SI’’
drugs. Determination of the state preference would only be
possible if we could measure the binding kinetics of individual
drugs. However, distinguishing slow association from association
to a slow-inactivated state is not trivial. In order to separate gating
kinetics from binding kinetics, a rapid pulse application of the drug
is necessary [32,36]. Even in this case, association and dissociation
rates cannot be correctly determined because the drug binding site
on sodium channels is not extracellularly localized. Therefore, the
onset rate of a drug effect may be determined by multiple
processes: aqueous phase – membrane partitioning, outer to inner
leaflet translocation, intramembrane diffusion and association,
itself. Any one of these may be the rate limiting step, which
obscures the microscopic association rate.
We investigated three well-known SCI drugs (lidocaine,
phenytoin and carbamazepine) and two antidepressants (fluoxetine
and desipramine). The uniquely high incidence of SCI activity
among antidepressants [2], as well as their high affinity to sodium
channels as compared to classic SCIs, suggests that the inhibition
of sodium channels may contribute to their therapeutic effect. The
therapeutic profile of antidepressants is different from that of
classic SCIs (anticonvulsants, local anesthetics, antiarrhythmics),
and we also intended to study whether the mechanism of
inhibition was similar to that of classic SCIs.
The experimental behavior of the five drugs was remarkably
similar to the behavior of prototypical drugs in simulations. We
suggest that lidocaine, phenytoin and carbamazepine stabilize the
fast-inactivated state, and that they have fast binding kinetics.
Their nSOD(Rec_t) – nSOD(SInact_t) plot clearly fell into the
‘‘fast area.’’ Furthermore, their effect on the ‘‘Rec_t’’ curve was
similar to the effect of ‘‘FI_fb.’’ Lidocaine behaved similarly to
‘‘FI_fb’’ in the ‘‘SInact_t’’ protocol as well. We hypothesized that
the moderate effect of phenytoin and carbamazepine was due to
their extra fast dissociation kinetics. This hypothesis was verified in
the case of carbamazepine, which produced the characteristic
Figure 6. The effect of five SCIs in different voltage protocols. The following drugs were investigated: 30 mM fluoxetine (FLX, black squares),
30 mM desipramine (DMI, black diamonds), 300 mM carbamazepine (CBZ, gray squares), 300 mM phenytoin (PHE, gray diamonds) and 300 mM lidocaine
(LID, gray circles). A, ‘‘FInact_V’’ protocol. Pre-pulse duration was set to 2 s. All drugs produced a similar voltage shift. B, ‘‘SInact_t’’ protocol.
Carbamazepine and phenytoin induced only a minor modification compared to the control. Fluoxetine and desipramine produced a definite shift.
Lidocaine caused inhibition even in the time range of fast inactivation. C, ‘‘Rec_t’’ protocol. Unlike fluoxetine and desipramine, carbamazepine,
phenytoin and lidocaine only affected the first phase of the curve, which corresponds with recovery from the fast-inactivated state. D, The
nSOD(Rec_t) – nSOD(SInact_t) plots for the drugs that were studied. Fluoxetine and desipramine occupied the overlapping area; plots of
carbamazepine, phenytoin and lidocaine fell into the area of fast-inactivated state stabilization.
doi:10.1371/journal.pcbi.1000818.g006
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tions to the protocol.
The nSOD(Rec_t) – nSOD(SInact_t) plots of fluoxetine and
desipramine fell into the overlapping area. Thus, their state
preference could not be unambiguously determined. However,
their properties of inhibition definitely differed from those of
classic SCIs.
Methods
Electrophysiology
Patch clamp electrophysiology was done on native sodium
channels in cultured hippocampal neurons. Cell culture prepara-
tion and electrophysiology were performed as published previously
[32]. Cultured hippocampal neurons (prepared on the 17
th day
after gestation) were found to express mostly the Nav1.2 and
Nav1.6 isoform, but Nav1.1, Nav1.3 and Nav1.7 isoforms were
also detected in a some cells [37]. In spite of the differences in
expression pattern biophysical properties of sodium currents were
remarkably similar [32,37], and potency of individual drugs
showed no higher variance than in experiments using Nav1.2
expressing HEK 239 cells (data not shown). Error bars on the
figures represent SEM, and the number of cells tested (n) was
between 4 to 10.
Ethics statement
All experimental procedures were approved by the Animal Care
and Experimentation Committee of the Institute of Experimental
Medicine, and as stated by the decision of the Animal Health and
Food Control Department of the Ministry of Agriculture and
Regional Development, were in accordance with 86/609/EEC/2
Directives of European Community.
Modeling
The simulation was based on a set of differential equations with
the occupancy of each state (i.e., the fraction of the ion channel
population in that specific state) given by the following equation:
dSi(t)
dt
~
X n
j
Sj(t)   kji{Si(t)   kij
  
ð1Þ
where Si(t) is the occupancy of a specific state at time t and Sj(t) is
the occupancy of a neighboring state. Neighboring states are states
where direct transitions are possible. n is the number of
neighboring states, and kij and kji are the rate constants of
transitions between neighboring states.
Differential equations were solved during simulations using a
fourth-order Runge-Kutta method. We used either Berkeley
Madonna v8.0.1 (http://www.berkeleymadonna.com/) or a
program written in C++.
Description of the tetracube (Hodgkin-Huxley type)
model. The model in itself, not including drug effects, is
equivalent to a modified Hodgkin-Huxley model of sodium
channels; the gates were assumed to move independently but in
a voltage-dependent manner. One modification is that, besides
activation and fast inactivation gates, we included a slow
inactivation gate. (The structural correlate of slow inactivation is
thought to be a collapse of the outer pore region [38]. This
mechanism may not be mechanistically called a gate, but for the
sake of simplicity, we will define ‘‘gate’’ functionally, and consider
any mechanism that can close and open the channel, a ‘‘gate’’.)
The model is phenomenological because we do not consider the
interdependence between gating processes (all of our major
findings were confirmed in a model where the processes of
activation and inactivation were coupled – see Text S1). For this
reason, individual states of the model do not necessarily
correspond with actual conformations of the real channel.
Channels were considered conducting when all three gates were
open. The topology of the model can be illustrated by constructing
a cube (Figure 7A), with the states forming the vertices and
conformational transitions forming the edges. Open or closed
conformations of the three gates (activation, fast inactivation and
slow inactivation gates) define individual states of the channel and
are shown by the three letters. The voltage-dependence of the rate
constants is defined by an exponential equation:
k~
A
1ze
(V1=2{V) r{1 ð2Þ
where the three free parameters A, V1/2 and r define the limiting
value, the inflection point and the maximal slope on the log rate
vs. voltage plot, respectively. The model thus far is no different
from a Hodgkin-Huxley type model (which also supposes the
independent movement of gates) except for the parameter ‘‘m’’
[39], which is not raised to the third power. The steepness of the
activation vs. voltage plot can be achieved by choosing appropriate
slope values for activation and deactivation, and the delay in the
activation vs. time plot can be ignored. Although there is no
difficulty in introducing multiple ‘‘m’’ particles in the state model,
we decided to avoid this for the sake of simplicity. A detailed
description of the model with numerical values of the 18 ‘‘ion
channel-specific’’ parameters is shown in Text S1 and Table S3.
These parameters reflect properties of the channel itself (not of the
drug); therefore they were kept constant in all simulations in this
study, except during the Monte Carlo study when the effect of the
‘‘ion channel-specific’’ parameters was investigated. ‘‘Drug-
specific’’ parameters are described in the following section.
‘‘Drug-specific’’ parameters: Introduction of drug effects
into the tetracube model. Because we supposed that drug
association to all states is possible, we connected a drug-bound
state to each vacant state, thus forming the tetracube (tesseract)
topology of the model (Figure 7B). Two additional (voltage-
independent) rate constants were defined: ka (association rate
constant; units: s
21mM
21) and kd (dissociation rate constant; units:
s
21). These were defined to determine the affinity of the drug to
the resting state. Drug-induced changes in gating rates were
simulated as predicted by the ‘‘modulated receptor hypothesis’’
[26,27], i.e., drug association to all states was made possible but
not with equal affinity. The model also incorporates one major
assumption of the ‘‘guarded receptor hypothesis’’ [24] in the sense
that besides increased affinity to the relevant inactivated state,
accessibility of the binding site (determining association and
dissociation rates) was also increased. The same three gate-specific
factors (CA, CF and CS) were used to determine both differences in
affinity (association-dissociation equilibria) and differences in the
relevant gating equilibria (for a detailed description of the model
see Text S1). Using this constraint, microscopic reversibility was
maintained in the model. Three constants were defined to
correspond to each of the three gates: ‘‘Closed Activation gate
stabilizing factor’’ (CA), ‘‘Closed Fast inactivation gate stabilizing
factor’’ (CF) and ‘‘Closed Slow inactivation gate stabilizing factor’’
(CS). Values larger than 1 were defined as being able to the closed
conformation of the gate, while values less than 1 stabilized the
open conformation. The calculation of individual rate constants is
described in Table S1 and Table S2.
In order to describe the specific drug effects on the channels, we
have defined five ‘‘drug-specific’’ parameters: ka, kd, CA, CF, and
Na
+ Channel Inhibitor Mechanisms
PLoS Computational Biology | www.ploscompbiol.org 10 June 2010 | Volume 6 | Issue 6 | e1000818CS. We assumed that drug-bound channels are blocked, i.e., they
are not able to conduct. This may not be true for all SCIs, but in
order to be able to explain inhibition at strongly hyperpolarizing
holding potentials (e.g. 2150 mV), this was the simplest hypothesis
to assume. Also, several SCIs have been shown to affect open
channels preferentially. In this study our aim was to follow the
dynamics of resting, fast inactivated and slow inactivated states in
the absence and presence of drugs, therefore we did not address
this mechanism, thus CA equaled 1 in all simulations.
While the affinity of the drug to resting channels is determined
by the ka/kd ratio, the apparent affinity to the whole channel
population, measured in a specific protocol must differ from this
value and is determined by all channel-specific and drug-specific
parameters, as well as by the parameters of the test protocol.
Description of the multi-step activation (MSA) model.
Although the tetracube model reproduces the voltage-dependent
kinetics of major gating transitions (activation, deactivation, fast
and slow inactivation, as well as recovery from both inacti-
vated states) fairly well, it obviously oversimplifies the gating
mechanisms. Most notably, unlike in real sodium channels,
activation is a single-step process, both types of inactivation are
voltage-dependent in themselves, and the gating transitions are
independent. A model in which activation is a multi-step process
with several intermediate states could better reproduce channel
behavior. In addition, using such a model, both fast and slow
inactivation themselves can be made voltage-independent
(deriving their voltage-dependence from the movement of
voltage sensors), which is a more correct approximation of real
channel behavior. Furthermore, using this type of model would
enable researchers to test alternative state preferences, such as the
preference for intermediate states [14,15,40]. This type of model
has been used previously in different studies [15,31,41], but none
of these models included slow inactivation. In order to verify our
conclusions obtained with the tetracube model, we built an MSA
model with both fast- and slow-inactivated states.
We used the model described by Kuo and Bean [31] as a
starting point. We used three-parameter exponential equations
(Eq. #2) to describe the voltage-dependence of the rate constants,
instead of the original two-parameter equations, because the latter
have no maxima, and therefore simulations tend to be unstable at
extreme membrane potential values.
In the model (Figure 7C), horizontal transitions (except the
rightmost one) correspond to the voltage-dependent move-
ment of voltage sensors, vertical transitions correspond to the
movement of the fast-inactivation particle, and backward-
forward transitions correspond to the movement of the slow
inactivation gate. This model, too, is considerably simplified: it
assumes that voltage sensors are identical and independent, that
opening requires all four voltage sensors to be in the depolarized
positions and that inactivation depends equally on the positions
of the four voltage-sensors. A detailed description of the states
and calculation of transitions are in Text S1, Table S1 and Table
S2; parameters of the model, and constraints for optimization
are in Table S4.
Figure 7. Topology of states in our models, as described in the text. A, Tetracube model of the drug-free channel. The position of the three
gates is illustrated as a section of a circle. (This arrangement makes no reference to the structure of sodium channels.) B, Formation of the tetracube:
Introduction of drug-bound states into the model. Drug association to all states was allowed. C, ‘‘Multi-step activation’’ (MSA) model of the drug-free
channel.
doi:10.1371/journal.pcbi.1000818.g007
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(‘‘FInact_V’’) and activation curves, as well as the ‘‘SInact_t’’
and ‘‘Rec_t’’ curves by both the tetracube and MSA models, are
shown in Figure S1. The MSA model was superior to the
tetracube model in the accuracy of the activation kinetics, but the
price for this is paid in a radically increased computational
demand (48 states and 224 transitions instead of 16 states and 64
transitions).
Introduction of drug effects into the MSA model. We
added drug-bound states, following the same principle as described
for the tetracube model (see Figure 7B). We doubled the number
of states (adding a drug-bound state for each unbound state), and
used the same factors (such as CF or CS) to calculate the differences
both in state-dependent affinity and in drug-binding-site-
occupancy-dependent gating equilibria (see Text S1, Table S1
and Table S2). (Note that, by this method, Markov-type models of
any complexity can be made to handle modulated receptor
hypothesis-based drug effects, while detailed balance in the model
is maintained.)
Monte Carlo simulations. In order to test the robustness of
our findings, we performed simulations with the tetracube model
using random parameters. The program was written in C++. The
constraints used for random number generation are given in Table
S3. Uniformly distributed random numbers were generated
between 0 and 1 and then transformed either linearly (in the
case of V1/2 values – see Eq. #2) or logarithmically (in the case of
A and r values – see Eq. #2) to match the limits shown in Table
S3.
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